Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

July 2021 in “ bioRxiv (Cold Spring Harbor Laboratory) ”

Ricardo Ariel Zimerman, Daniel do Nascimento Fonseca, Michael do Nascimento Correia, Renan Nascimento Barros, Dirce Costa Onety, Karla Cristina Petruccelli Israel, Emilyn Oliveira Guerreiro, José Erique Miranda Medeiros, Raquel Neves Nicolau, Luiza Fernanda Mendonça Nicolau, Rafael Xavier Cunha, Maria Fernanda Rodrigues Barroco, Patrícia Souza da Silva, Raysa Wanzeller de Souza Paulain, Claudia Elizabeth Thompson, Andy Goren, Carlos Gustavo Wambier, Flavio Cadegiani

proxalutamide non-steroidal antiandrogen

Studysummary This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study explored the effects of proxalutamide, a non-steroidal antiandrogen, on the 28-day mortality rate of hospitalized COVID-19 patients. In a randomized clinical trial with 580 participants, those who completed a 14-day proxalutamide treatment had a significantly lower mortality rate of 4.2% compared to 49.0% in the placebo group. The study found that treatment adherence was crucial, as early interruption of proxalutamide led to a high mortality rate of 79.3%. The results suggested that ensuring treatment compliance could enhance the drug's efficacy in reducing mortality among COVID-19 patients.

View this study on medrxiv.org →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

42 citations , July 2021 in “Frontiers in Medicine”

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

41 citations , February 2021 in “Cureus”

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

research Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users

21 citations , February 2021 in “BMJ case reports”

This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

research Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men

49 citations , January 2021 in “Journal of The European Academy of Dermatology and Venereology”

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

research COVID-19, Androgens, and Androgenic Alopecia

6 citations , December 2020 in “Dermatological reviews”

This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.

research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

36 citations , November 2020 in “Journal of The European Academy of Dermatology and Venereology”

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

This article is a discussion piece that examines the clinical symptoms of hyperandrogenic women with COVID-19, without reporting new research findings.

research Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective

34 citations , September 2020 in “BMC Endocrine Disorders”

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

research Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

32 citations , July 2020 in “Journal of The American Academy of Dermatology”

This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations , May 2020 in “Journal of The American Academy of Dermatology”

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.